HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: prognostic significance of low expression of bax.

Abstract
A randomized trial has demonstrated that concurrent chemoradiotherapy (CRT) is superior to radiotherapy (RT) alone in locally advanced nasopharyngeal cancer (NPC). Our study comprise 35 patients with locally advanced NPC (stage I: 1, II: 12, III: 7, IV: 15) with 1 cycle of induction chemotherapy (5-fluorouracil 1,000 mg/m(2)/day and cisplatin 20 mg/m(2)/day, days 1- 4) followed by concurrent CRT starting on day 22. Concurrent CRT consisted of RT (70 Gy/35 fractions for 7 weeks) with cisplatin 20 mg/m(2)/day for 4 days on weeks 1, 4, 7 of RT. Complete response (CR) was achieved in 33 patients (94%). Four-year progression-free survival (PFS) and overall survival (OS) of all patients were 57% and 65%, respectively. In analysis of prognostic factors, low expression of bax was the most significant independent predictor of poor prognosis in both PFS (p=0.002) and OS (p=0.008). In conclusion, the outcome of patients treated with this combined therapeutical modality appears to be comparable with that of Intergroup 0099 trial with high CR rate. Low expression of bax was significantly associated with poor PFS and OS.
AuthorsS Y Kang, Y T Oh, J H Han, J-H Choi, H-Y Lim, H I Kim, H-W Lee, J H Jang, J S Park, H C Kim, S Kang, M Chun, C H Kim, H J Joo
JournalNeoplasma (Neoplasma) Vol. 53 Issue 5 Pg. 450-6 ( 2006) ISSN: 0028-2685 [Print] Slovakia
PMID17013542 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • bcl-2-Associated X Protein
  • Cisplatin
  • Fluorouracil
Topics
  • Adult
  • Antineoplastic Agents (therapeutic use)
  • Biomarkers, Tumor (analysis)
  • Cisplatin (therapeutic use)
  • Combined Modality Therapy
  • Female
  • Fluorouracil (therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Nasopharyngeal Neoplasms (drug therapy, mortality, radiotherapy)
  • Prognosis
  • Survival Analysis
  • bcl-2-Associated X Protein (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: